Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Core Insights - Coherus BioSciences has completed the divestiture of its UDENYCA franchise to Intas Pharmaceuticals for a deal valued at up to $558.4 million, receiving an upfront payment of $483.4 million [1][3] - The company now has a post-close cash balance of $250 million, extending its cash runway into 2027, which will support the development of its oncology pipeline [1][2] - Coherus is focusing on its innovative oncology programs, particularly the growth of LOQTORZI revenues and advancing its immuno-oncology candidates [2][5] Transaction Details - The transaction closed on April 11, 2025, with Coherus receiving $483.4 million upfront, including $118.4 million for UDENYCA inventory, and potential milestone payments of up to $75 million based on net sales [1][3] - Intas received assets related to the UDENYCA franchise, including pre-filled syringes and autoinjectors, and assumed certain liabilities [3] Company Overview - Coherus is a commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI, and a promising pipeline targeting various cancers [5] - The company aims to grow LOQTORZI sales in nasopharyngeal carcinoma and develop new indications in combination with its pipeline candidates [5] Pipeline Information - Coherus' immuno-oncology pipeline includes multiple antibody candidates, such as Casdozokitug, an IL-27 antagonist, and CHS-114, a selective anti-CCR8 antibody, currently in various clinical studies [6][9]